5 Key Takeaways

• 1

  UCLA researchers engineered CAR-T cells to block VEGF, enhancing their ability to attack solid tumors and dismantle protective microenvironments.

• 2

  The modified CAR-T cells release a VEGF-blocking antibody locally within tumors, avoiding systemic side effects associated with traditional anti-VEGF drugs.

• 3

  In preclinical models, armored CAR-T cells significantly outperformed standard CAR-T therapies and systemic anti-VEGF treatments in glioblastoma and ovarian cancer.

• 4

  The engineered CAR-T therapy improved survival rates and boosted immune signaling in ovarian cancer models, while eliminating tumors in a majority of glioma cases.

• 5

  This research indicates a shift in immunotherapy, focusing on engineering CAR-T cells to reshape tumor environments for enhanced cancer treatment efficacy.